Introduction
Mitochondria1 monoamine oxidase (MAO; EC 1.4.3.4) catalyses the oxidative deamination of a variety of primary, secondary and tertiary amines. Until very recently most of the attention concerning MA0 activity was focused on the reaction of this enzyme to deaminate neurotransmitter substances, including adrenaline, noradrenaline, serotonin and dopamine. The ability of MA0 to regulate the intraneuronal concentration of aminergic neurotransmitters and tissue concentrations of other sympathomimetic amines, such as tyramine, phenylethylamine and tryptamine, conferred a detoxifying role on this enzyme (see [l, 2J for reviews). However, more recent studies and developments in the reaction kinetics of MA0 indicate that this enzyme may have other functional roles and, indeed, may be involved in converting rather inert tertiary amines, such as the Parkinson-inducing dopaminergic neurotoxin MPTP (N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) to the neuroactive metabolite MPP+ (N-methyl-4-phenyl-l,2-dihydropyridinium ion) [3] . Thus, MA0 has also been assigned a role in the pathogenesis of Parkinson's disease, resulting from its ability to convert (oxidize) environmental MPTP-like neurotoxins to reactive metabolites. Although MPTP is a synthetic amine, such suggestions cannot be ignored, even though no such Parkinson disease-inducing environmental neurotoxin has so far been identified in the environment or the human brain.
In this paper we wish to describe a recentlydiscovered novel property of MA0 involving its ability to convert novel inert secondary and tertiary amines into neuroactive substances with neurotransmitter properties, as a prerequisite for the treatment of neurological disorders of epilepsy, myoclonus, spinal spasticity, depressive illness and Parkinson's disease.
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Aliphatic and aromatic amine derivatives of glycine and y-aminobutyric acid y-Aminobutyric acid (GABA) and glycine constitute the major inhibitory neurotransmitters in the brain [4] . Both neurotransmitters have been implicated in epilepsy, myoclonus, tardive dyskinesia, Huntington's chorea, schizophrenia and even in Parkinson's disease. However, neither amino acid crosses the blood-brain barrier (BBB). Although a limited number of metabolic inhibitors and agonists of GABA exist, so far no similar drugs exist for glycine. Thus the role of glycine in brain function and neurological diseases has been difficult to assess [4] . In normal circumstances, glycine is considered a major inhibitory neurotransmitter in the brain stem and upper spinal cord motor interneurons. Even so, it is now recognized that glycine also has an excitatoxin property in the hippocampus via its allosteric interaction with the Nmethyl-u-aspartate (NMDA) receptor, a subtype of the glutamate receptor [ 51.
Milacemide (2-n-pentylaminoacetamide) is a secondary monoamine glycine derivative with a reported anticonvulsant activity equivalent to valproate in numerous animal models [6-91. Unlike glycine it readily crosses the BBB, where its major pathway ( > 90%) of metabolism is dealkylation to the metabolites glycineamide and glycine [6-101 (Fig. 1) Besides being a selective substrate of MAO-B with a relatively high affinity for this enzyme (Km=30-8O p~) as compared with MAO-A ( K , = 1200-1500 p~) , milacemide also acts as a time-dependent, enzyme-activated, partially-reversible specific inhibitor of MAO-B [13] (Fig. 1) . A reversible inhibition of MAO-A is also observed at high concentrations. Formation of a putative intermediate imine as an inhibitor bound reversibly to the enzyme has been suspected. Thus milacemide Table I The kinetic parameters of oxidation of MAO-A and MAO-6 substrates Values for M A 0 substrates are compared with the newly-developed aliphatic and aromatic monoamine derivatives of glycine and y-aminobutyric acid using guinea-pig brain mitochondria1 preparation. n.d., not determined. 1 (2-n-pentylaminodiacetamide) was oxidized equally by MAO-A and B. As a whole the GABA derivatives are poorer substrates for both enzyme forms, although they have a slightly greater affinity for the B enzyme. Like milacemide, compounds 1 and 2 are enzyme-activated, partially-reversible specific inhibitors of MAO-B in vitro and in viva Their in vivo inhibitory activity on amine metabolism have not been examined: however, preliminary studies in rats do indicate that they possess anticonvulsant activity in buccuculin-and picrotoxininduced convulsion. It remains to be determined whether the latter property is associated with their metabolites.
The phenomenon that brain-impenetrable amino acids (e.g. glycine) can be made to pass the BBB, when coupled to a non-polar MAO-B substrate (e.g. pentylamine and phenylethylamine) is an important concept. This process could be an extremely useful procedure by which other drugs can be transported across the BBB. . Brains obtained at autopsy frcm I-deprenyl-treated Parkinson's disease subjects have shown that both dopamine and phenylethylamine are increased in extrapyramidal regions (caudate nucleus, substantia nigra, putamen and globus pallidus). However, the increase ( > 3500%) in phenylethylamine is substantially greater than that of dopamine which can also be oxidized by MAO-A [17] . This has led to the suggestion [20] that phenylethylamine could act as a sustained modulator of dopamine release, because of its amphetamine-like action.
Other endogenous MAO-B substrates
Besides its ability to potentiate the pharmacological action of dopamine formed from L-dopa [ 161, I-deprenyl is thought to have neuroprotective activity in nigro-striatal dopamine neurons in Parkinson's disease [ 181. The recent confirmation of this hypothesis [19, 211 does not allow any conclusion about the mechanisms of the possible neuroprotective action of I-deprenyl to be drawn. This mechanism may not necessarily depend on the inhibition of oxygen free radicals formed from and polyamines were beginning to appear (see [2] for review). This led Blaschko [3] to introduce terminology based on the sensitivity of a particular amine oxidase to carbonyl reagents such as semicarbazide and hydroxylamine. that 'carbonyl reagent' should be replaced by 'semicarbazide' since some carbonyl reagents were also active against the first group of enzymes while semicarbazide was not. Since the introduction of this classification, a number of additions have been made and the name SSAO has gained in acceptance. Such additions include lysyl oxidase (proteinlysine 6-oxidase; EC 1.4.3.13) [6] and an assortment of tissue-bound amine oxidases found mainly in brown and white fat as well as smooth muscles, especially those of blood vessels. The SSAO group appears to grow inexorably and, as yet, the great majority of its constituent enzymes have no rigorously defined name. Several trivial names have been used to describe both these tissue-bound and the plasma enzymes, including benzylamine oxidase and clorgyline-resistant amine oxidase [ 41.
However, SSAO appears to be the most suitable name at present since the criterion for an enzyme to be included in this group is that its .ability to catalyse oxidative deamination is inhibited by semicarbazide. No other characteristic is required for inclusion. SSAO, like MAO, catalyses a double-displacement, or ping-pong reaction, although it would appear to be of the aminotransferase type: E-CHO + R-CHZ-NH, -E-CHZ-NH, + R-CHO E-CHZ-NHZ + 0, + HZO -E-CHO + NH, + HZOZ In such a reaction, release of ammonia is dependent upon O,, whereas MA0 can release NH, anaerobically. This, along with studies on the kinetics of inhibition of product formation, favour the aminotransferase pathway [7, 8] . Volume 19 
